Tavo Espinoza

Tavo Espinoza

Chief Financial OfficeratLigand Pharmaceuticals· In proxies 2022–2025

Pay in FY2025+33% from the year before · Ligand Pharmaceuticals stock +76.5% the same year

Tavo Espinoza was paid $4.4M in FY2025 (Dec), up 33%. Ligand Pharmaceuticals stock rose 76.5% that year.

Pay$100 in the stock at the end of FY21 → $122
Pay is from the Summary Compensation Table of each Ligand Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Ligand PharmaceuticalsPublic company · 4 yr
    • Chief Financial Officer2022 – Present · 4 yrStock in role +99%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?